Unimed Pharmaceutical: A subsidiary plans to increase capital to acquire 51% equity of GuKang Pharmaceuticals.

On the evening of June 24, Wumei Pharmaceutical announced that its wholly-owned subsidiary, Wumei in Shanghai, plans to increase its capital by 45 million yuan to acquire a 51% stake in Sichuan Gu Kang Pharmaceutical Co., Ltd. Through increasing the capital of Gu Kang Pharmaceutical, Wumei in Shanghai intends to actively explore opportunities in the fields of Chinese medicinal materials, Chinese patent medicine, and the biological asset market, carefully plan asset development strategies, determine reasonable operational models, integrate high-quality internal and external resources to revitalize assets, and promote the improvement of asset operation efficiency. As a Chinese medicinal material and Chinese patent medicine enterprise with a mature commercial system, Gu Kang Pharmaceutical has certain market share and stable customer resources, and complementary channel networks and product types to the company's existing business.